Acuitas Therapeutics Inc. v. GlaxoSmithKline Biologicals SA
1:25-cv-00003
Overview
Parties
Defendant
GlaxoSmithKline LLC NPE (University / Research)
Represented By
4 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
GlaxoSmithKline Biologicals SA NPE (University / Research)
Represented By
4 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Plaintiff
Acuitas Therapeutics Inc. Operating Company
Represented By
12 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young Conaway Stargatt & Taylor, LLP
1000 N. King Street, Wilmington, DE 19801
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🌐 PCT International (WIPO) | PCT World Application | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 8 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US11638693
Vaccine for eliciting immune response comprising RNA encoding an immunogen and lipid formulations comprising mole percentage of lipids
|
Filed: 2022-06-23
Issued: 2023-05-02
|
Active (4.6 yrs remaining)
Expires: 2031-07-06
|
|
|
US11638694
Vaccine for eliciting immune response comprising lipid formulations and RNA encoding multiple immunogens
|
Filed: 2022-06-23
Issued: 2023-05-02
|
Active (4.6 yrs remaining)
Expires: 2031-07-06
|
|
|
US11666534
Methods of administering lipid formulations with viral immunogens
|
Filed: 2021-12-22
Issued: 2023-06-06
|
Active (15.1 yrs remaining)
Expires: 2041-12-22
|
|
|
US11766401
Methods of administering lipid formulations with immunogens
|
Filed: 2021-12-22
Issued: 2023-09-26
|
Active (15.1 yrs remaining)
Expires: 2041-12-22
|
|
|
US11786467
Lipid formulations with immunogens
|
Filed: 2021-12-22
Issued: 2023-10-17
|
Active (15.1 yrs remaining)
Expires: 2041-12-22
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. Standard Maintenance Fee Schedule Tracked.
Procedural Motions & Interlocutory Orders
Total Motions
20
Dispositive
14
Granted
3
Denied
0
Pending / Review
14
Motions by Category
Key Dispositive Motions & Rulings